Study offers ongoing HAE treatment access for prior trial participants

NCT ID NCT04933721

First seen Oct 31, 2025 · Last updated May 04, 2026 · Updated 23 times

Summary

This study gives people with hereditary angioedema (HAE) who were in earlier berotralstat trials continued access to the medication. About 139 participants will receive the drug and be monitored for side effects and safety. The goal is to keep providing treatment while gathering long-term safety information.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study Center

    Ottawa, Canada

  • Study Center

    Brno, Czechia

  • Study Center

    Pilsen, Czechia

  • Study Center

    Grenoble, France

  • Study Center

    Marseille, France

  • Study Center

    Paris, France

  • Study Center

    Frankfurt, Germany

  • Study Center

    Skopje, North Macedonia

  • Study Center

    Krakow, Poland

  • Study Center

    Martin, Slovakia

  • Study Center

    Cape Town, South Africa

  • Study Center

    Daegu, South Korea

  • Study Center

    Gwangju, South Korea

  • Study Center

    Seoul, South Korea

  • Study Center

    Madrid, Spain

  • Study Center

    Bristol, United Kingdom

Conditions

Explore the condition pages connected to this study.